A fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesions

Autor: Gert Auer, Lotta Wik, Ulf Landegren, Annika Eriksson, Susanne Becker, Jonas Kierkegaard, Rolf Lewensohn, Andrey Alexeyenko, Masood Kamali-Moghaddam, Naveen R Muppani, Bo Franzén, Thomas Hatschek
Rok vydání: 2018
Předmět:
0301 basic medicine
Oncology
Cancer Research
Receptor
ErbB-2
Cell- och molekylärbiologi
Aftercare
Chemokine CXCL9
Cohort Studies
0302 clinical medicine
Multiplex
Sampling (medicine)
Breast
fine‐needle aspiration
Research Articles
Aged
80 and over
Furin
Membrane Glycoproteins
medicine.diagnostic_test
breast cancer diagnosis
General Medicine
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Neoplasm Proteins
3. Good health
Fine-needle aspiration
030220 oncology & carcinogenesis
Intercellular Signaling Peptides and Proteins
Molecular Medicine
Immunohistochemistry
Female
Decorin
Research Article
Adult
medicine.medical_specialty
Biopsy
Fine-Needle
Breast Neoplasms
lcsh:RC254-282
Young Adult
03 medical and health sciences
Breast cancer
Internal medicine
Biopsy
Biomarkers
Tumor
Genetics
medicine
Humans
fine-needle aspiration
Aged
Analysis of Variance
Cancer och onkologi
business.industry
Cancer
medicine.disease
Early Diagnosis
030104 developmental biology
Cancer and Oncology
proximity extension assay
Cancer biomarkers
protein biomarker
Carrier Proteins
business
Heme Oxygenase-1
Cell and Molecular Biology
Zdroj: Molecular Oncology
Molecular Oncology, Vol 12, Iss 9, Pp 1415-1428 (2018)
ISSN: 1878-0261
1574-7891
DOI: 10.1002/1878-0261.12350
Popis: There are increasing demands for informative cancer biomarkers, accessible via minimally invasive procedures, both for initial diagnostics and to follow‐up personalized cancer therapy. Fine‐needle aspiration (FNA) biopsy provides ready access to relevant tissues; however, the minute sample amounts require sensitive multiplex molecular analysis to achieve clinical utility. We have applied proximity extension assays (PEA) and NanoString (NS) technology for analyses of proteins and of RNA, respectively, in FNA samples. Using samples from patients with breast cancer (BC, n = 25) or benign lesions (n = 33), we demonstrate that these FNA‐based molecular analyses (a) can offer high sensitivity and reproducibility, (b) may provide correct diagnosis in shorter time and at a lower cost than current practice, (c) correlate with results from routine analysis (i.e., benchmarking against immunohistochemistry tests for ER, PR, HER2, and Ki67), and (d) may also help identify new markers related to immunotherapy. A specific 11‐protein signature, including FGF binding protein 1, decorin, and furin, distinguished all cancer patient samples from all benign lesions in our main cohort and in smaller replication cohort. Due to the minimally traumatic sampling and rich molecular information, this combined proteomics and transcriptomic methodology is promising for diagnostics and evaluation of treatment efficacy in BC.
Databáze: OpenAIRE
Externí odkaz: